The performance has "double declined" and the stock price "continues to fall". Why did bloomage biotechnology corporation limited's growth engine stall?
① Bloomage Biotechnology Corporation Limited once again experienced a double decline in revenue and net income in the first half of the year. The company achieved revenue of 2.81 billion yuan, a year-on-year decrease of 8.61%; achieved net income of 0.342 billion yuan, a year-on-year decrease of 19.51%; ② Although the raw materials business and medical terminal business performed well, the two major new sectors that have been heavily promoted in recent years - functional skincare products and functional food - have experienced a simultaneous decline in growth rates.
The gross margin of injection products in the solution category has declined, and the imeik technology development's Q2 performance growth rate has dropped to single digits| Speed reading announcement.
①Imeik Technology Development's H1 revenue and net income growth rate slowed down. ②The gross margin of solution injection products has declined, and its proportion in total revenue has further decreased. ③In addition to laying out research and development pipelines for botulinum toxin, GLP-1 drugs, the company is also further expanding in the medical beauty equipment field.
Meituan sets its sights on small businesses like nail salons.
Explore the potential of the industry chain.
How long can the American customer love myth of high growth last? | Insight Research
Despite 3 consecutive years of high performance growth, market concerns about Aimeike's future growth momentum have not been resolved.
Behind the slowdown in Aimeike's growth rate in the 3rd quarter: “Women's Maotai” can't handle the slump in consumption?
Demand weakens
Medical beauty earns 200 million dollars a month and has to participate in the internal volume of diet pills. Where is the boundary of America's ambition?
It's not easy to take diet pills